Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.

Detalles Bibliográficos
Autores principales: Arora, Rishi, Martin, Michelle T, Boike, Justin, Patel, Sonalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011907/
https://www.ncbi.nlm.nih.gov/pubmed/36926235
http://dx.doi.org/10.4254/wjh.v15.i2.318
_version_ 1784906504656125952
author Arora, Rishi
Martin, Michelle T
Boike, Justin
Patel, Sonalie
author_facet Arora, Rishi
Martin, Michelle T
Boike, Justin
Patel, Sonalie
author_sort Arora, Rishi
collection PubMed
description Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.
format Online
Article
Text
id pubmed-10011907
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100119072023-03-15 Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment Arora, Rishi Martin, Michelle T Boike, Justin Patel, Sonalie World J Hepatol Letter to the Editor Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals. Baishideng Publishing Group Inc 2023-02-27 2023-02-27 /pmc/articles/PMC10011907/ /pubmed/36926235 http://dx.doi.org/10.4254/wjh.v15.i2.318 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Letter to the Editor
Arora, Rishi
Martin, Michelle T
Boike, Justin
Patel, Sonalie
Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title_full Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title_fullStr Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title_full_unstemmed Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title_short Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
title_sort glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis c virus treatment
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011907/
https://www.ncbi.nlm.nih.gov/pubmed/36926235
http://dx.doi.org/10.4254/wjh.v15.i2.318
work_keys_str_mv AT arorarishi glecaprevirpibrentasvirsofosbuvirforpostlivertransplantrecurrenthepatitiscvirustreatment
AT martinmichellet glecaprevirpibrentasvirsofosbuvirforpostlivertransplantrecurrenthepatitiscvirustreatment
AT boikejustin glecaprevirpibrentasvirsofosbuvirforpostlivertransplantrecurrenthepatitiscvirustreatment
AT patelsonalie glecaprevirpibrentasvirsofosbuvirforpostlivertransplantrecurrenthepatitiscvirustreatment

Ejemplares similares